Clinical Trial Update: Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 trial updating TB treatment by adding amikacin during the first treatment week to prevent acquired resistance in multidrug-resistant tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis Multidrug-resistant

Drugs mentioned

• Amikacin (amikacin)

Snippet

Sponsor: Rwanda Biomedical Centre | Conditions: Tuberculosis, Multidrug-Resistant | Phase 2 | Status: UNKNOWN